SEED Company Profile

Confronting the difficulties, the Eiger Biopharmaceuticals Inc in the financial fourth quarter of 2022

For the financial time-frame closing December 31 2022 Eiger Biopharmaceuticals Inc managed to reduce its losses on dwindling revenue, where shortfall per share were at $-0.46 compared to $-0.64 and revenue decreased by -19.762 % to $2.70 millions in contrast to $3.36 millions in the corresponding reporting period a year ago.

For the fourth quarter of 2022 SESG had turn a round to income by exhibiting earnings per share of $1.89 per share compare to $-0.64 a year ago and earnings per share turned positive from $-2.11 per share from the preceding quarter.

Sales remained unchanged to $0.00 millions from $3.36 millions in the same quarter a year ago and sequentially Sales Tumbled from $0.00 millions.

Compelling time frame by Federal Home Loan Bank Of Boston in the fourth quarter of 2022

For the financial fourth quarter of 2022 Federal Home Loan Bank Of Boston reached zero gain of $0.00 per share compare to $0.00 a year ago and from $0.00 per share from the prior reporting season.

Sales rose strongly by 54.111 % to $75.28 millions from $48.85 millions in the comparable reporting season a year ago and sequentially Sales deteriorated by -13.874 % from $87.41 millions.

ABEV has achieved Bottom and Top-line rise for the financial time-frame ending December 31 2022. Sales were at $15.14 billions increased by 9.409 % year on year and deteriorated by 0 % quarter on quarter, while net profit per share grew by 14.17 % to $0.17, sequentially by 0 %.

Severe hit for Wisa Technologies Inc in the fourth quarter of 2022

Wisa Technologies Inc declared disastrous fiscal time-frame ending December 31 2022, where Sales faded by -54.2 % to $0.92 millions and net deficit per share has expanded to $-0.23, from the corresponding reporting season a year ago.